MOMATE Mometasone Furoate 1mg / g (0.1%) Cream 5g
RXDRUG-DR-XY29551
Discreet Packaging
FDA-registered Products
FDA-licensed Pharmacies
Indications/Uses
Relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses eg, psoriasis and atopic dermatitis. Momate may be applied to scalp lesions.
Dosage/Direction for Use
A thin film of cream/oint should be applied to the affected area once daily.
Overdosage
Symptoms: Excessive prolonged use of topical corticosteroids can suppress pituitary-adrenal function resulting in secondary adrenal insufficiency.
Treatment: Appropriate symptomatic treatment is indicated, acute hypercorticoid symptoms are virtually reversible. Treat electrolyte imbalance, if necessary. In cases of chronic toxicity, slow withdrawal of corticosteroids is advised.
Treatment: Appropriate symptomatic treatment is indicated, acute hypercorticoid symptoms are virtually reversible. Treat electrolyte imbalance, if necessary. In cases of chronic toxicity, slow withdrawal of corticosteroids is advised.
Special Precautions
If irritation or sensitization develops with the use of Momate, treatment should be discontinued and appropriate therapy instituted. In the presence of infection, use of an appropriate antifungal or antibacterial agent should be instituted. If a favourable response does not occur promptly, the corticosteroid should be discontinued until the infection is controlled adequately. Any of the side effects that have been reported following systemic use of corticosteroids, including adrenal suppression, may also occur with topical corticosteroid, especially in infants and children. Systemic absorption of topical corticosteroids will be increased if extensive body surface areas are treated or if the occlusive technique is used.
The cream/ointment is not for ophthalmic use.
Use in pregnancy & lactation: Since safe use of Momate in pregnant women has not been established, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of these class should not be used on pregnant patients in large amounts or for prolonged periods of time.
It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breastmilk. Systemically administered corticosteroids are secreted into breastmilk in quantities not likely to have deleterious effect on the infant. Nevertheless, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Use in children: Suitable precautions should be taken when long-term use is anticipated, particularly in infants and children. Paediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced-hypothalamic pituitary axis suppression and Cushing's syndrome than mature patients because of a larger skin surface to body weight ratio. Use of topical corticosteroids in children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with growth and development of children.
The cream/ointment is not for ophthalmic use.
Use in pregnancy & lactation: Since safe use of Momate in pregnant women has not been established, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of these class should not be used on pregnant patients in large amounts or for prolonged periods of time.
It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breastmilk. Systemically administered corticosteroids are secreted into breastmilk in quantities not likely to have deleterious effect on the infant. Nevertheless, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Use in children: Suitable precautions should be taken when long-term use is anticipated, particularly in infants and children. Paediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced-hypothalamic pituitary axis suppression and Cushing's syndrome than mature patients because of a larger skin surface to body weight ratio. Use of topical corticosteroids in children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with growth and development of children.
Adverse Reactions
Local adverse reactions reported very rarely with Momate includes paresthesia, pruritus and signs of skin atrophy. The following adverse reactions have been reported infrequently with the use of other topical corticosteroids: Irritation, hypertrichosis, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, striae and miliaria.
Storage
Store at temperatures not exceeding 30°C. Do not freeze.
Action
Mometasone furoate, a synthetic corticosteroid exhibits its anti-inflammatory, antipruritic and vasoconstrictive properties.
MedsGo Class
Topical Corticosteroids
Features
Brand
Momate
Full Details
Dosage Strength
0.1% (1mg /g )
Drug Ingredients
- Mometasone
Drug Packaging
Cream 5g
Generic Name
Mometasone Furoate
Dosage Form
Cream
Registration Number
DR-XY29551
Drug Classification
Prescription Drug (RX)
Please sign in so that we can notify you about a reply